Combination of arsenic and interferon alpha for the treatment of myeloproliferative disorders

The present invention relates to methods and pharmaceutical compositions for the treatment of myeloproliferative disorders in patients presenting a dysregulation of the JAK2-STAT signalling pathway. In particular, the present invention relates to a method of treating a myeloproliferative disorder in a patient presenting a dysregulation of the JAK2-STAT signalling pathway comprising administering to the patient a therapeutically effective combination of an interferon polypeptide and an arsenic compound.

Keywords: Melanoma, Combination, Myeloproliferative disorders
Patent Application number: EP17305053.5
Inventors:
Jean-luc VILLEVALJean-Jacques KILADJIANValérie LALLEMAND-BREITENBACHIsabelle PLOBruno CASSINATHugues BLAUDIN DE THE
Publications:
Int J Cancer 2014 Feb 15;134(4):988-96

Reference:

BIO16455-T1

Business Developper
contact
Anne COCHI
Anne COCHI
Business Development Manager
Patent filling date: 2017-01-18
Second indication: Yes

You might also be interested in